Application of breast cancer marker and breast cancer diagnosis kit
By inhibiting the expression of breast cancer marker USP36 and regulating the polyubiquitination of ERα protein, the problems of endocrine resistance and tamoxifen resistance in breast cancer patients are solved, and the effectiveness of breast cancer treatment is improved.
Patent Information
- Application Number
- CN202411179116.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-27
- Publication Date
- 2024-11-12
AI Technical Summary
The prior art is difficult to effectively solve the endocrine resistance problem in breast cancer patients, especially tamoxifen resistance, and it is not clear which deubiquitinases play a key role in estrogen signaling and endocrine resistance.
By detecting and inhibiting the expression of the breast cancer marker USP36, and regulating the K48-linked polyubiquitination of the ERα protein, a breast cancer diagnostic kit and therapeutic drug are developed to improve the sensitivity of breast cancer therapeutic drugs.
Determined as a key deubiquitinase involved in ERα signaling and breast cancer progression, USP36 can restore the sensitivity of tamoxifen by inhibiting USP36, providing a potential treatment for breast cancer and improving ER-positive breasts. The therapeutic effect of cancer.
Smart Images

Figure CN118937678A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to an application of a breast cancer marker and a kit for diagnosing breast cancer. Background Art
[0002] There are approximately 1 million new cases of breast cancer each year worldwide, and breast cancer is the most common malignancy in women. Based on molecular pathology, breast cancer is divided into four types: type A, type B, type HER2, and triple negative (TNBC). Both luminal type A and type B breast cancer are characterized by estrogen receptor α (ERα) positivity. ERα is a nuclear receptor that plays an important role in the occurrence and development of breast cancer by controlling cell transformation, proliferation, and metastasis. ERα is one of the subtypes of ER, and the connection between breast cancer and estrogen signaling has been known for more than 80 years. In 1985, ESR1 was cloned and is the main driver of the carcinogenic process of luminal breast cancer. The ERα protein is composed of 595 amino acids, including the transactivation domain 1 (AF1), the ligand binding domain (LBD), and the DNA binding domain (DBD). Tamoxifen is a selective endoplasmic reticulum modulator that can effectively target the endoplasmic reticulum signaling pathway and play a role in the prevention and treatment of breast cancer in patients with ER-positive breast cancer. Tamoxifen is similar in structure to estradiol, competes with estrogen for DNA binding, and blocks the expression of ERα target genes. The emergence of endocrine resistance is a pressing clinical issue, and approximately 30-40% of breast cancer patients will inevitably develop endocrine resistance. Many regulatory models, including protein post-translational modifications (PTMs), have been proposed in some studies to elucidate the potential mechanisms of endocrine resistance.
[0003] Ubiquitination is a widespread post-translational modification of proteins that plays a key role in regulating various cellular functions. The ubiquitination process is reversible and can be catalyzed by a series of deubiquitinases called deubiquitinases (DUBs). As far as we know, there are about 100 deubiquitinases encoded in the human genome, but it is still unclear which deubiquitinases play a key role in estrogen signaling and endocrine resistance, and no application of deubiquitinases has been seen. Summary of the invention
[0004] In order to solve the above technical problems, the present invention provides an application of a breast cancer marker and a kit for diagnosing breast cancer.
[0005] Any of the following applications:
[0006] (a) Use of a preparation for detecting breast cancer marker USP36 in the preparation of a breast cancer diagnostic product;
[0007] (b) Use of a preparation for inhibiting the expression of breast cancer marker USP36 in the preparation of a breast cancer treatment product;
[0008] (c) Application of breast cancer marker USP36 in improving the sensitivity of breast cancer treatment drugs.
[0009] Preferably, the diagnostic product is a diagnostic reagent for detecting the expression level of USP36.
[0010] Preferably, the diagnostic reagent includes a reagent for detecting the expression level of USP36 protein in a sample using proteome sequencing technology.
[0011] Preferably, the diagnostic reagent includes a reagent for detecting the expression level of the USP36 gene in a sample using sequencing technology, probe hybridization technology, gene chip technology or fluorescent quantitative PCR technology.
[0012] Preferably, the agent for inhibiting the expression of breast cancer marker USP36 inhibits K48-linked polyubiquitination of ERα protein.
[0013] Preferably, the agent for inhibiting the expression of breast cancer marker USP36 is a nucleotide sequence shown in any one of SEQ ID NO.1-SEQ ID NO.2, SEQ ID NO.3-SEQ ID NO.4, SEQ ID NO.7-SEQ ID NO.8 or SEQ ID NO.9-SEQ ID NO.10.
[0014] Preferably, the breast cancer therapeutic drug is tamoxifen.
[0015] A kit for diagnosing breast cancer, comprising a reagent for detecting the expression level of USP36 in a sample.
[0016] Preferably, the sample is from a breast cancer patient, a suspected breast cancer patient, a breast cancer susceptible population, a breast cancer high-risk population, or a healthy population;
[0017] Preferably, the sample is tissue or cell.
[0018] The present study showed that the deubiquitinase USP36 plays a key role in regulating ERα ubiquitination and tamoxifen resistance. USP36 is associated with gene markers of ERα signaling and is associated with ER-positive breast cancer and poor survival in tamoxifen treatment. Mechanistically, we found that USP36 promotes the development of breast cancer by regulating K48-related deubiquitination of ERα protein, thereby enhancing ERα signaling activity and tamoxifen resistance. Our results highlight the central role of USP36 in regulating ERα ubiquitination, thereby increasing its stability. Further studies confirmed that the interaction between USP36 and ERα promotes the deubiquitination of ERα. These results highlight the potential of USP36 as a therapeutic target for addressing tamoxifen resistance.
[0019] ERα has been considered a promising prognostic biomarker and is essential for guiding the treatment of breast cancer. Tamoxifen is a widely used treatment for patients with ER-positive breast cancer. Unfortunately, 30-40% of breast cancer patients eventually develop tamoxifen resistance, which is a pressing clinical problem. Multiple studies have proposed a variety of regulatory models to elucidate tamoxifen resistance, including conversion to an ERα-negative state and the presence of constitutively active mutations in specific functional domains of ERα. However, in most cases of tamoxifen resistance, the ER is still expressed and activated, indicating that there are other mechanisms regulating ESR1 to confer tamoxifen resistance. Increasing evidence shows that the expression of ESR1 is regulated by multiple aspects, including post-translational modifications (PTMs), histone modifications, SUMOylation, somatic mutations, and ESR1 fusion genes. As breast cancer patients face the challenge of endocrine resistance, understanding the activity of ERα signaling, including its expression and stability regulation, is crucial for the development of new anti-estrogen therapies and overcoming tamoxifen resistance.
[0020] Ubiquitination is a widespread protein post-translational modification (PTM). Recent studies have found increasing evidence that E3 ubiquitin ligases affect ERα signaling and tamoxifen sensitivity. Our previous studies have shown that SMURF1, TRIM56, and RNF181 can interact with ERα to promote breast cancer growth. The deubiquitination process of DUBs, that is, the reversal of protein hydrolysis mediated by the ubiquitin-proteasome system, has been shown to have a huge impact on a variety of cellular processes, including immune response and drug resistance. As far as we know, there are about 100 deubiquitinases encoded in the human genome, but it is not clear which deubiquitinases play a key role in estrogen signaling and endocrine resistance. Therefore, in order to detect deubiquitinases that may be involved in ER signaling, a genome-wide siRNA screening of DUB enzymes was performed. In addition, USP36 was found to be positively correlated with genes downstream of ER signaling and was associated with shortened survival in ER-positive breast cancer.
[0021] USP36 is a member of the ubiquitin-specific protease (USP) family and a deubiquitinating enzyme. Recent studies have shown that USP36 plays a key role in a variety of cell biological processes by deubiquitinating proteins. This process leads to reduced proteasomal degradation of proteins involved in tumorigenesis, immune response, cell cycle progression, and autophagy. Our previous studies have shown that USP36 plays a crucial role in regulating Hippo signaling activity by inhibiting YAP / TAZ K48-linkedpolybiquitination. In the invention, it was found that USP36 promotes breast cancer development by regulating K48-associated deubiquitination of ERα proteins, thereby enhancing ERα signaling activity. More importantly, it was also found that elevated USP36 levels were associated with reduced survival in breast cancer patients treated with tamoxifen. In addition, in endocrine-resistant breast cancer cell models, knocking down USP36 restored its sensitivity both in vivo and in vitro.
[0022] In summary, the results suggest that USP36 modifies the ubiquitination of ER and tamoxifen resistance and may provide a new therapeutic target for the treatment of breast cancer. A novel modulator of estrogen signaling that modulates USP36 activity or gene expression levels may be an attractive therapeutic option for breast cancer. In addition, further studies are needed to understand the role of DUBs in ERα and tamoxifen resistance, as well as to evaluate their therapeutic potential in various tamoxifen resistance models.
[0023] Compared with the prior art, the present invention has the following beneficial effects:
[0024] The present invention identifies ubiquitin-specific peptidase 36 (USP36) as a key deubiquitinase involved in ERα signaling and breast cancer progression. In vitro and in vivo studies have shown that USP36 can promote the progression of breast cancer through the ERα signaling pathway. Conversely, knocking down USP36 inhibits tumorigenesis. In a model resistant to endocrine therapy, knocking down USP36 disrupted the stability of the ERα(Y537S) resistant form and restored sensitivity to tamoxifen. Molecular studies have shown that USP36 inhibits K48-associated ERα polyubiquitination and enhances the ERα transcriptome. Therefore, the present invention shows that USP36 is a new biomarker for the treatment of breast cancer, revealing that inhibiting USP36 in combination with tamoxifen may provide a potential treatment for breast cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1Figure 2 shows the identification of USP36 as a novel ER signaling mediator in ER-positive breast cancer; A shows the siRNA screening procedure, B is the relative expression level of TFF1 (PS2) in MCF-7 cells transfected with the screening library DUB; the qRT-PCR results of siControl were normalized to 1; C is the expression of USP36 in breast cancer tissues (n=1097) and normal tissues (n=114) from the TCGA database (https: / / www.genome.gov / ); D is the relative expression level of USP36 in breast cancer tissues (n=1097) and normal tissues (n=114) from the TCGA database Expression of USP36 in ER-positive breast cancer tissues (n=566) and normal tissues (n=114); E shows that high expression of USP36 in ER-positive breast cancer is associated with poor prognosis of patients, and F shows that high expression of USP36 in ER-negative breast cancer is not associated with prognosis of patients; G is immunohistochemical detection of USP36 expression in 65 breast cancer samples and 55 normal breast tissues; H is statistical analysis of USP36 expression; I is a volcano plot of RNA-seq data of MCF-7 cell line treated with siControl or siUSP36; |log2Fold change|>1 and P value <0.05 were the screening criteria; J was the MCF-7 cell line treated with siControl or siUSP36, with a threshold of P<0.05 and Fold change>1.5, and KEGG analysis was performed on the down-regulated genes in the RNA-seq data; K was the gene set enrichment analysis (GSEA) showing that estrogen-responsive genes were enriched in the RNA-seq data of the MCF-7 cell line treated with siControl or siUSP36; L was the heat map of differential ER pathway-related genes in the RNA-seq data, with a threshold of P<0.05 and Fold change>1.5; M was the gene set enrichment analysis, and TCGA data showed that estrogen-responsive genes were enriched in breast cancer tissues, with a threshold of P<0.05 and Fold change>1.5; all P values were calculated using unpaired two-tailed Student's t test; *p<0.05; **p<0.01; ***p<0.001;
[0026] Figure 2The results show that USP36 depletion inhibits the progression of ER-positive breast cancer in vivo and in vitro; A is the level of USP36 mRNA in MCF-7 cells; B is the cell viability detected by CCK-8 method in MCF-7 cells at the specified time points; C is the colony formation of MCF-7 cells; D is the quantitative analysis of the results of colony formation experiment of MCF-7 cells; E is the result of Transwell method to detect the migration ability of MCF-7 cells; F is the quantitative analysis of Transwell assay results; G is the result of wound healing assay to detect the migration ability of MCF-7 cells; H is the quantitative analysis of wound healing assay; I is the percentage of apoptotic cells in MCF-7 cells detected by flow cytometry; J is the quantitative result of apoptotic cells in MCF-7 cells; K shows that nude mice injected with stably transfected shControl or shUSP36 MCF-7 cells developed tumors; L shows the tumor volume of nude mice subcutaneously inoculated with stably transfected shControl or shUSP36 MCF-7 cells; M shows the tumor volume of nude mice subcutaneously inoculated with stably transfected shControl or shUSP36 Tumor weight of nude mice with MCF-7 cells; Three independent experiments were performed to obtain the results shown in Figures AM; All data are expressed as mean ± standard deviation; *p < 0.05; **p < 0.01; ***P < 0.001 (Student t test);
[0027] Figure 3 The results show that overexpression of USP36, but not USP36 C131A, promotes the progression of ER-positive breast cancer in vivo and in vitro; A is immunoblot analysis showing the expression level of USP36 in MCF-7 cells transfected with Flag or Flag-USP36 WT or Flag-USP36 C131A plasmids, with β-actin as the internal control; B is immunoblot analysis showing the expression level of USP36 in MCF-7 cells transfected with Flag or Flag-USP36 WT or Flag-USP36 C131A plasmids, with β-actin as the internal control. Cell viability of MCF-7 cells transfected with C131A plasmid for 48 hours at the indicated time points; C is the colony formation of MCF-7 cells 48 hours after transfection with the indicated plasmid; D is the quantitative analysis of C; E is the migration ability of MCF-7 cells detected by Transwell method 48 hours after transfection; F is the quantitative analysis of E; G is the migration ability of MCF-7 cells transfected with the indicated plasmid for 48 hours, and the wound healing assay was used to detect the migration ability; H is the quantitative analysis of G; I shows representative images of tumors obtained from nude mice injected with stably transfected MCF-7 cells; J is the tumor volume of nude mice subcutaneously inoculated with stably transfected MCF-7 cells; K is the tumor weight of nude mice subcutaneously inoculated with stably transfected MCF-7 cells; Three independent experiments were performed to obtain the results shown in Figures AK; All data are expressed as mean ± standard deviation; *p<0.05; **p<0.01; ***P<0.001 (Student's t test);
[0028] Figure 4 Showing that USP36 but not USP36 C131A is required for the ERα signaling pathway in breast cancer; MCF-7 cells were transiently transfected with 20 nM siControl or 20 nM siUSP36 and then treated with 10 nM estradiol or vehicle for 6 h; cell lysates were immunoblotted with the indicated antibodies; β-actin was used as an internal control, and the results are A: Western blotting to detect USP36 and ERα protein levels in MCF-7 cells; MCF-7 cells were transiently transfected with Flag or Flag-USP36 for 48 h and then treated with 10 nM estradiol or vehicle for 6 h; cell lysates were immunoblotted with the indicated antibodies; β-actin was used as an internal control, and the results are B: Western blotting to detect USP36 and ERα protein levels in MCF-7 cells;
[0029] C: MCF-7 cells were transiently transfected with 20 nM siControl or 20 nM siUSP36 after treatment according to the indicated method, and then treated with 10 nM estradiol or vehicle for 6 h, and the mRNA levels of PS2, PDZK1, GREB1, and PKIB were detected by qRT-PCR; D: Luciferase activity of MCF-7 cells was detected by luciferase assay; E: MCF-7 cells were transiently transfected with Flag or Flag-USP36 for 48 h, and then treated with 10 nM estradiol or vehicle for 6 h, and the mRNA levels of PS2, PDZK1, GREB1, and PKIB were detected by qRT-PCR; F: Luciferase activity of MCF-7 cells was detected by luciferase assay; G: MCF-7 cells were transiently transfected with Flag or Flag-USP36 WT or Flag-USP36 MCF-7 cells were transiently transfected with C131A plasmid for 48 hours, and the protein levels of USP36 and ERα were detected by western blotting; H was transiently transfected with Flag or Flag-USP36 CA31A for 48 hours in MCF-7 cells, and then treated with 10nM estradiol or vehicle for 6 hours, and the mRNA levels of PS2, PDZK1, GREB1 and PKIB were detected by qRT-PCR; I was immunohistochemical detection of USP36 expression in ER-positive breast cancer and ER-negative breast cancer in 65 breast cancer patients; J was the statistics of USP36 expression; in Figures AJ, the results are representatives of three independent experiments; all data are expressed as mean ± standard deviation; *p<0.05; **P<0.01; ***P<0.001 (Student's t test);
[0030] Figure 5 Diagram of a hypothetical model for the mechanism by which USP36 regulates ERα signaling. DETAILED DESCRIPTION
[0031] The specific embodiments of the present invention are described in detail below, but it should be understood that the protection scope of the present invention is not limited by the specific embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work belong to the protection scope of the present invention. The experimental methods described in the embodiments of the present invention are conventional methods unless otherwise specified.
[0032]
[0033] Cell line and cell culture information: The MCF-7 cell line was obtained from the American Type Culture Collection (ATCC) and cultured in Dulbecco's modified Eagle's medium (DMEM, D6429, Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS, 10270-106, Gibco), 4.5 g / L glucose, and 4 mM / L-glutamine. Cells were incubated in charcoal-stripped FBS (Gibco, 12676-029) and treated with DMEM without phenol red (Gibco, 11330-057) for E2. All cell lines were authenticated by short tandem repeat (STR) analysis, and the STR data of the MCF-7 cell line matched the data provided by ATCC.
[0034] Plasmid and siRNA information: Myc-USP36 and Flag-USP36 plasmids were donated by Wenhao Zhang. Lipofectamine 2000 (1662298, Invitrogen) was used for transfection according to the manufacturer's instructions. When the cell confluence reached 40-60%, siRNA was transfected using Lipofectamine RNAi MAX (3778-075, Invitrogen 1). As shown in Table 1, siRNA or shRNA was synthesized for USP36 by GenePharma (China).
[0035] Table 1 siRNA sequences
[0036]
[0037] It should be noted that the F sequence and R sequence of siUSP36#1, siUSP36#2 and siControl were all connected to the base TT at the 3' end when used.
[0038] The experimental operations involved in the present invention are all carried out according to the following methods.
[0039] DUB siRNA library screening
[0040] Human deubiquitinase (ON-TARGET plus) was obtained from the Dharmacon siRNA library (GU-104705) containing 76 human DUBs. ER-positive breast cancer cells MCF-7 were transfected with different siDUBs for 48 h, RNA was isolated, and reverse transcribed into cDNA. The expression level of TFF1 (PS2), a classical downstream gene of ERα, was analyzed to explore the potential regulation of ERα signaling pathway. The qRT-PCR results of siControl were normalized, and the gene sequences are shown in Supplementary Table 2
[0041] RNA extraction and qRT-PCR analysis
[0042] Cellular RNA was extracted using the RNeasy Plus Mini Kit (Tiangen, DP451) according to the manufacturer's instructions. The extracted RNA was reverse transcribed using HiScript IIQ RT SuperMix (Vazyme, R223-01) according to the manufacturer's instructions. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed on a 7500 Fast Real-Time PCR System (Applied Biosystems, Singapore) using SYBR qRT-PCR MasterMix (Vazyme, Q511-02). 36B4 was used as an internal reference gene. The primer sequences for the qRT-PCR experiment are as follows: The relative expression levels were determined using the 2-ΔΔCt method. The primers used were composed of Sangon Biotech, and the specific primers are shown in Table 2.
[0043] Table 2 Primers used in qRT-PCR
[0044]
[0045]
[0046] Western blotting and co-immunoprecipitation (Co-IP) assay
[0047] For Western blotting, cells were collected and lysed with Western and IP lysis buffer (P0013J, Beyotime) supplemented with protease and phosphatase inhibitors (Thermo). The concentration of protein was determined by Bradford protein assay. Subsequently, 20-30 μg of protein was separated using sdpolyacrylamide gel electrophoresis (PAGE), and then the protein was transferred to a PVDF membrane (Millipore). Primary antibody was used. After washing three times with PBST, secondary antibody (Beyotime, A0216, 1:600 or Beyotime, A0208, 1:600) was applied. The signal was visualized using ECL Western blotting substrate.
[0048] For co-immunoprecipitation experiments, 500 μg of protein lysate was pre-cleared with 20 μL protein A+ / G+ agarose (Beyotime, P2028) and rabbit IgG (Beyotime, A7016, 1:50) at 4°C for 2 hours. Immunoprecipitation was then performed at 4°C for 4 hours with the specified antibodies. Negative controls included rabbit IgG (Beyotime, A7016, 1:50) or mouse IgG (Beyotime, A7028, 1:50). Western blot analysis was performed using the specified antibodies. The antibodies used are listed in Table 3.
[0049] Table 3 Antibody information
[0050] Target Source No.ofCatalogue Anti-USP36(R) Proteintech 14783-1-AP Anti-USP36(M) Proteintech 68165-1-Ig Anti-ERα(R) CellSignalingTechnology 8644 Anti-β-Actin(R) CellSignalingTechnology 3700 Anti-HA(R) CellSignalingTechnology 3724 Anti-UB(R) Proteintech 10201-2-AP Anti-Flag(R) Sigma-Aldrich F9291 Anti-Myc(R) Abcam Ab9106 RabbitIgG Beyotime A7016 MouseIgG Beyotime A7028 GoatAnti-RabbitIgG Beyotime A0208 GoatAnti-MouseIgG Beyotime A2016 Protein A+GAgarose Beyotime P2028
[0051] Luciferase activity assay
[0052] Estrogen signaling luciferase activity was detected using the Dual-Luciferase Reporter Kit from Promega, Germany. Cells were transfected with Renilla ERE luciferase reporter gene. Luciferase activity was measured 24 hours after treatment according to the manufacturer's instructions.
[0053] CCK8 assay
[0054] Cell viability was determined using a cell counting kit (CCK-8), and 4 × 103 cells were plated in a 96-well plate. Proliferation levels were assessed at designated time intervals: 24, 48, and 72 h. Optical density (OD) values at 450 nm were quantified using a multifunctional enzyme-linked analyzer (BioTek, USA).
[0055] Colony formation assay
[0056] MCF-7 and T47D cells were transfected with 20 nM USP36 siRNA and 20 nM siControl in 24-well plates. Two weeks later, colony formation assays were performed as described above.
[0057] Transwell experiment
[0058] Migration experiments were performed in uncoated Transwell chambers with a pore size of 8 μm (Corning, USA). First, the upper chamber was inoculated with 5×10 4 The lower chamber was inoculated with 500 μL of medium containing 20% FBS. After 24 hours of incubation, the cells that crossed the lower surface of the membrane were fixed and stained with 4% paraformaldehyde and hematoxylin. Subsequently, the cells from three randomly selected fields were counted as triplicates of the experiment.
[0059] Wound healing assay
[0060] MCF-7 and T47D cells were transfected with siUSP36 or siControl in 6-well plates until confluence and used for wound healing assays. Subsequently, a linear scratch was created along the straight edge using a 200 μL yellow sterile tip gun. After the scratch was initiated, the closure of the scratch was monitored and photographed microscopically at designated time intervals. The distance between the two borders was measured and compared with the original distance at designated times.
[0061] Apoptosis analysis
[0062] In the apoptosis experiment, Annexin V and propidium iodide (PI) staining was performed on MCF-7 and T47D cells using Vazyme's Annexin V-fitc apoptosis detection kit (#A211-02). Fluorescence intensity was quantified using FACScan (Millipore), and data were analyzed using forward scatter (FSC) using Flowjo7.6 software.
[0063] Protein stability assay
[0064] The half-life of endogenously or exogenously expressed ERα was determined by cycloheximide (CHX) chase. Cells were transfected with 50 nM siControl / siUSP36 or 1 μg vector / Flag-USP36 WT / Flag-USP36 mutants and cultured in 12-well plates. After 48 h, cells were treated with 100 μM cycloheximide (C7698, Sigma) for the indicated times. Next, ERα degradation was detected by immunoblotting and immunoblotting of equal amounts of boiled lysates.
[0065] Polyubiquitination detection experiment
[0066] Take K48-linked polyubiquitination as an example. Cells were co-transfected with K48 Ub plasmid and Flag ERα-tagged Myc-USP36 or Myc, and K48-linked ERα polyubiquitination was detected in cell extracts. 24 hours after transfection, cells were exposed to MG132 at a concentration of 10 μM for 6 hours. Protein extraction was then performed, followed by pre-clearing with protein A for 2 hours. Anti-ERα or anti-Flag antibodies were incubated with the extracts overnight, followed by incubation with protein A / G beads at 4°C for 1 hour. Finally, Western blot was performed using anti-HA antibody to detect total polyubiquitinated ERα or K48 polyubiquitinated ERα.
[0067] Immunofluorescence analysis
[0068] Cover slips were placed in 12-well cell culture plates of MCF-7 cells. After 24 h of incubation, MCF-7 cells on coverslips were immediately fixed with 4% paraformaldehyde for 15 min, permeabilized with 0.25% Triton X-100 for 15 min, and blocked with 5% BSA for 1 h. Subsequently, coverslips were incubated with primary antibodies specific for USP36 and ERα at 4°C overnight. After rinsing with PBS, coverslips were exposed to secondary antibodies labeled with fluorophores (Invitrogen), and cell nuclei were stained with DAPI (Beyotime). Negative controls were incubated with secondary antibodies only, without primary antibodies. Images were acquired using a Nikon A+ laser scanning confocal microscope, and image processing and assembly were performed using ImageJ software.
[0069] Public clinical data analysis
[0070] Breast cancer tumor RNA-seq data from USP36 are available through the Genomic Data Commons (GDC) data portal. Data analysis and calculations were performed using Prism 9.0 software. In addition, we analyzed the expression of USP36 in ER-positive, ER-negative breast cancer tissues and normal tissues from the TCGA database. The KMPLOT database (https: / / kmplot.com) was used to analyze the relationship between USP36 expression and clinical prognosis.
[0071] RNA sequencing data analysis
[0072] Pathway analysis of differentially expressed genes (DEGs) was performed using marker gene sets and KEGG pathways in metscape (https: / / metascape.org), and the statistical significance thresholds for differentially expressed genes (DEGs) were P < 0.05 and fold change > 1.5. Visualization of the results was created in the form of heat maps using a free data analysis and visualization platform located at http: / / www.bioinformatics.com.cn. Subsequently, a volcano plot was generated using the OmicStudio tool found at https: / / www.omicstudio.cn / tool to display differentially expressed genes (DEGs) that met the set criteria (P < 0.05 and fold change > 2). Gene set enrichment analysis (GSEA) used the HALLMARKS_ESTROGEN_RESPONSE_LATE gene set from the Molecular Database v7.4. Gene Set Enrichment Analysis (GSEA) was performed using GSEA4.1.0 software with standard default settings.
[0073] Xenograft mouse model
[0074] Female M-NSG mice, 4 weeks old, were implanted with 17β-estradiol sustained-release pellets (0.72 mg / 90 days, from Innovative Research of America) purchased from Shanghai Model Organism Center. There were 6 mice in each group. After 24 hours, each mouse was injected with approximately 4×10 6 MCF-7 cells and Matrigel solution. Subsequently, tumor size was measured every 5 days. Tumor volume was determined as the width squared multiplied by the length and then divided by 2. The Ethics Committee of Xinxiang Medical College approved all procedures involving animal experiments. Throughout the study, mice were housed in a controlled environment, maintained at a specific pathogen-free (SPF) level, with regulated temperature and lighting conditions (12 h light / 12 h dark cycle), and provided with free access to food and water.
[0075] statistics
[0076] Statistical analysis used in this study included Student's t-test, Pearson correlation coefficient, and Cox regression analysis, using publicly available data. Data are presented as mean ± standard deviation (SD), and statistical significance was defined as P < 0.05 (*), P < 0.01 (**), and P < 0.001 (***).
[0077] Example 1
[0078] Identification of USP36 as a novel mediator of ER signaling in ER-positive breast cancer
[0079] siRNA screening against whole genome DUB enzymes was used to detect deubiquitinating enzymes that can regulate ERα signaling activity. DUB siRNA library (Dharmacon Company, Cat: G104705) was used for siRNA screening in MCF-7 cells. Figure 1 As shown in A, it is used to identify novel deubiquitinases involved in regulating ER signaling; in MCF-7 cells, each of the 76 human DUB genes was knocked down with 20 μM siRNA; after 48 hours, real-time PCR was used to detect quantitative gene expression. TFF1 (PS2) is a recognized ERα target gene. To evaluate ERα signaling activity, PS2 was used as an indicator. Data analysis showed that knockdown of USP36 significantly reduced PS2 mRNA levels in MCF-7 cells, as shown in Figure 1 As shown in B. Knockdown of several other DUBs such as PSMD14 and USP1 significantly reduced the expression of PS2 mRNA.
[0080] We further examined the expression of USP36 in human breast cancer and found that based on data from the TCGA database, USP36 levels were elevated in breast malignancies, such as Figure 1 C. In addition, USP36 expression was elevated in ER-positive breast cancer samples, as shown in Figure 1 D. The relationship between USP36 and breast cancer survival was investigated using data from the TCGA database (https: / / kmplot.com / analysis / ). Kaplan-Meier analysis of public meta-analysis data showed that high USP36 levels were associated with shorter survival in patients with ER-positive breast cancer, as shown in Figure 2. Figure 1 E. Further analysis showed that USP36 was not associated with survival in patients with ER-negative breast cancer, suggesting that the effect of USP36 on survival may depend on ER status, such as Figure 1 As shown in Figure F (https: / / kmplot.com). Immunohistochemistry (IHC) was used to evaluate the protein level of USP36 in breast cancer patient samples. The results showed that the expression of USP36 in breast cancer was also significantly increased. Among 55 normal breast tissues, only 11 cases were positive for USP36; but among 65 breast cancer patients, 43 cases were positive for USP36. P<0.001; Figure 1 G-1H, which is consistent with the results from the TCGA database, such as Figure 1 As shown in C.
[0081] In addition, USP36 was further knocked down in MCF-7 cells for RNA sequencing analysis (GSE262678). The volcano plot showed 590 change points, such as Figure 1As shown in I. Hallmark gene set and KEGG pathway analysis on metscape (https: / / metascape.org) showed that knocking down USP36 affected various aspects of cancer biological processes. Among the downregulated signaling pathways, estrogen signaling ranked first, such as Figure 1 J. In addition, GSEA (gene set enrichment analysis) showed that the HALLMARK_ESTROGEN RESPONSE gene set was reduced overall under the condition of USP36 knockdown, as shown in Figure 1 K. In addition, heat map analysis showed that knockdown of USP36 could effectively reduce the mRNA expression of classic ERα target genes TFF1, GREB1, PDZK1, and IL20, as shown in Figure 1 In addition, GSEA showed that the HALLMARK_ESTROGEN RESPONSE gene set features were significantly enriched in the case of high expression of USP36, as shown in Figure 1 As shown in M.
[0082] Based on these results, we suggest that USP36 may be a potential enhancer of ER signaling in breast cancer.
[0083] Example 2
[0084] Knockdown of USP36 inhibits the progression of ER-positive breast cancer in vivo and in vitro
[0085] The effect of USP36 on the phenotype of ER-positive breast cancer was further investigated by reducing the level of USP36 in MCF-7 cells. After 48 h of USP36 siRNA treatment, the level of USP36 mRNA in MCF-7 cells was detected by qRT-PCR. Figure 2 As shown in A, knockdown of USP36 was confirmed by qRT-PCR, and cell viability was measured by CCK-8 assay at indicated time points in MCF-7 cells transfected with siControl or siUSP36 for 48 h. Figure 2 As shown in B, the loss of USP36 significantly impaired the proliferation of ER-positive breast cancer cells. In addition, colony formation assays showed that knocking down USP36 reduced colony formation ability after transfection with scrambled siRNA or two independent USP36 siRNAs for 48 hours. Figure 2 As shown in C-2D, the Transwell assay showed that knocking down USP36 reduced the migration ability of MCF-7 cells. Figure 2 As shown in E-2F, the results of the wound healing experiment also confirmed this conclusion. Figure 2 In addition, after MCF-7 cells were treated with USP36 siRNA for 48 h, the percentage of apoptotic cells was detected by flow cytometry (FACS). Figure 2 As shown in I-2J, the effect of USP36 on apoptosis of MCF-7 cells was analyzed. Propidium iodide (PI) / Annexin V staining showed that knockdown of USP36 resulted in a higher proportion of apoptotic cells in the cells. In addition, nude mice were randomly divided into two groups and subcutaneously injected with shControl or shUSP36 to establish a subcutaneous xenograft tumorigenesis model. The xenograft mouse model confirmed that silencing USP36 in MCF-7 cells can inhibit tumor growth in vivo, as shown in Figure 2. Figure 2 K-2M shown.
[0086] Overall, USP36 significantly promoted the progression of ER-positive breast cancer.
[0087] Example 3
[0088] USP36 overexpression promotes ER-positive breast cancer in vivo and in vitro
[0089] To further investigate the effect of USP36 on the phenotype of ER-positive breast cancer, Flag or Flag-USP36 WT or Flag-USP36 C131A plasmids were transfected for 48 h, and USP36 WT and USP36C131A were successfully obtained by overexpressing USP36 wild-type (WT) plasmid and USP36 catalytically inactive mutant (C131A), as verified by Western blotting. Figure 3 As shown in A. CCK-8 assay showed that USP36 overexpression significantly promoted the proliferation of ER-positive breast cancer cells, rather than its catalytically inactive mutant (C131A). Figure 3 As shown in B. Colony formation assay showed that overexpression of USP36 increased colony formation ability, but overexpression of C131A did not. Figure 3 C-3D. Transwell experiments also showed that overexpression of USP36, but not USP36 C131A, could enhance the migration ability of MCF-7 cells. Figure 3 In addition, in the wound healing assay, the wound healing rate was significantly increased in MCF-7 cells overexpressing USP36, but not USP36 C131A, as shown in E-3F. Figure 3 In addition, xenograft mouse models confirmed that overexpression of USP36 WT promoted tumor growth in vivo compared with USP36 C131A. Figure 3 As shown in I-3K.
[0090] Example 4
[0091] USP36 but not USP36 C131A is required for ERα signaling in breast cancer
[0092] Since ERα plays a crucial role in estrogen signaling, the effect of USP36 on ERα protein was investigated. Knockdown of USP36 reduced ERα protein levels under control and estradiol-treated conditions, as shown in Figure 4 A. qRT-PCR data showed that knockdown of USP36 suppressed the expression of ERα target genes, including GREB1, PS2, PKIB, and PDZK1, not only under vehicle treatment but also under estradiol treatment, as shown in Figure 4 As shown in C.
[0093] Estrogen response element (ERE) luciferase assay was performed in MCF-7 cells to investigate the effect of USP36 knockdown on ERα transcriptional activity. The results showed that after knockdown of USP36, ERE luciferase activity was significantly reduced, as shown in Figure 5. Figure 4 D. In contrast, overexpression of USP36 in MCF-7 cells enhanced the expression of ERα protein, ERα signaling target genes, and signaling activity under vehicle and estradiol treatment, as shown in Figure 4 B, 4E-4F. In addition, it was found that the catalytically inactive mutant of USP36 (C131A) had no effect on ERα signaling, as shown in Figure 4 G-4H. Immunohistochemical analysis of another 65 breast cancer samples showed that USP36 was positively correlated with ERα, as shown in Figure 4 As shown in I-4J.
[0094] A hypothetical model diagram showing the mechanism by which USP36 regulates ERα signaling, such as Figure 5 shown.
[0095] It should be noted that when the claims of the present invention involve numerical ranges, it should be understood that the two endpoints of each numerical range and any numerical value between the two endpoints can be selected. In order to avoid redundancy, the present invention describes a preferred embodiment.
[0096] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.
[0097] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.
Claims
1. Any of the following applications: (a) Use of a preparation for detecting breast cancer marker USP36 in the preparation of a breast cancer diagnostic product; (b) Use of a preparation for inhibiting the expression of breast cancer marker USP36 in the preparation of a breast cancer treatment product; (c) Application of breast cancer marker USP36 in improving the sensitivity of breast cancer treatment drugs.
2. The use according to claim 1, It is characterized in that The diagnostic product is a diagnostic reagent for detecting the expression level of USP36.
3. The use according to claim 2, It is characterized in that The diagnostic reagent includes a reagent for detecting the expression level of USP36 protein in a sample using proteome sequencing technology.
4. The use according to claim 2, It is characterized in that The diagnostic reagent includes a reagent for detecting the expression level of USP36 gene in a sample by using sequencing technology, probe hybridization technology, gene chip technology or fluorescent quantitative PCR technology.
5. The use according to claim 1, It is characterized in that The agent for inhibiting the expression of the breast cancer marker USP36 inhibits the K48-linked polyubiquitination of the ERα protein.
6. The use according to claim 1, It is characterized in that The preparation for inhibiting the expression of breast cancer marker USP36 is a nucleotide sequence shown in any one of SEQ ID NO.1-SEQ ID NO.2, SEQ ID NO.3-SEQ ID NO.4, SEQ ID NO.7-SEQ ID NO.8 or SEQ ID NO.9-SEQ ID NO.
10.
7. The use according to claim 1, It is characterized in that The breast cancer treatment drug is tamoxifen.
8. A kit for diagnosing breast cancer, It is characterized in that The kit comprises a reagent for detecting the expression level of USP36 as claimed in claim 2 in a sample.
9. The kit according to claim 8, It is characterized in that The samples are from breast cancer patients, suspected breast cancer patients, people susceptible to breast cancer, people at high risk of breast cancer or healthy people.
10. The kit according to claim 9, It is characterized in that The sample is tissue or cell.
